Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Guan Z, Xu B, DeSilvio M, Newstat B, Moore Y, Makhson A. 5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71492-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]

For:	Guan Z, Xu B, DeSilvio M, Newstat B, Moore Y, Makhson A. 5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71492-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]

Number

Cited by Other Article(s)

Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, Green M, Francis P, De Boer R, Colosimo M, Chua S, Chirgwin J, Beith J, Bell R. Systemic treatment of HER2-positive metastatic breast cancer: A systematic review. Asia Pac J Clin Oncol 2014;10 Suppl S4:1-14. [DOI: 10.1111/ajco.12206] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/01/2014] [Indexed: 11/30/2022]